These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 3247497)

  • 1. Inhibition of monoamine oxidase by 3,4-dihydroxyphenyl 1-alanine and its analogs.
    DeFeudis FV
    Rev Clin Basic Pharm; 1988; 7(1-4):207-8. PubMed ID: 3247497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of monoamine oxidase by 3,4-dihydroxyphenyl L-alanine and its analogues.
    Naoi M; Nagatsu T
    Life Sci; 1987 Jan; 40(4):321-8. PubMed ID: 3100896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.
    Finberg JP; Gross A; Bar-Am O; Friedman R; Loboda Y; Youdim MB
    Br J Pharmacol; 2006 Nov; 149(6):647-56. PubMed ID: 17016505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver.
    Ozaita A; Olmos G; Boronat MA; Lizcano JM; Unzeta M; García-Sevilla JA
    Br J Pharmacol; 1997 Jul; 121(5):901-12. PubMed ID: 9222546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro inhibition of rat monoamine oxidase by liquiritigenin and isoliquiritigenin isolated from Sinofranchetia chinensis.
    Pan X; Kong LD; Zhang Y; Cheng CH; Tan RX
    Acta Pharmacol Sin; 2000 Oct; 21(10):949-53. PubMed ID: 11501051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors.
    Herraiz T; Chaparro C
    Biochem Biophys Res Commun; 2005 Jan; 326(2):378-86. PubMed ID: 15582589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances.
    Sjöqvist F
    Proc R Soc Med; 1965 Nov; 58(11 Part 2):967-78. PubMed ID: 4952963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke.
    Khalil AA; Davies B; Castagnoli N
    Bioorg Med Chem; 2006 May; 14(10):3392-8. PubMed ID: 16458520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of L-dopa on epinephrine concentration in rat brain: possible role of inhibition of norepinephrine N-methyltransferase by S-adenosylhomocysteine.
    Fuller RW; Hemrick-Luecke SK; Perry KW
    J Pharmacol Exp Ther; 1982 Oct; 223(1):84-9. PubMed ID: 7120131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photoaffinity labeling of human placental monoamine oxidase-A by 4-fluoro-3-nitrophenyl azide.
    Hsu MC; Shih JC
    Mol Pharmacol; 1988 Feb; 33(2):237-41. PubMed ID: 3340083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of monoamine oxidase (MAO) by α-ethylphenethylamine and N,α-diethylphenethylamine, two compounds related to dietary supplements.
    Santillo MF
    Food Chem Toxicol; 2014 Dec; 74():265-9. PubMed ID: 25455893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Centrally mediated increased reflex vagal bradycardia after L-dopa in monoamine oxidase-inhibited anesthetized dogs.
    Antonaccio MJ; Kerwin L
    J Pharmacol Exp Ther; 1976 Feb; 196(2):380-8. PubMed ID: 1255483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-dopa therapy for Parkinson's disease: past, present, and future.
    Nagatsua T; Sawadab M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
    Palfreyman MG; McDonald IA; Zreika M; Cremer G; Haegele KD; Bey P
    J Neural Transm Suppl; 1993; 40():101-11. PubMed ID: 8294896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S; Zheng H; Fridkin M; Youdim MB
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Fernandez HH; Chen JJ
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.